Semaglutide Reduces Cardiovascular Events 20% Beyond Weight Loss in SELECT Subanalysis

The SELECT trial randomized overweight or obese adults to semaglutide or placebo and previously reported a 20% relative reduction in the composite of cardiovascular death, myocardial infarction, or stroke. This new mediation analysis tracked serial risk-factor trajectories over two years and applied statistical decomposition to quantify how much of the outcome benefit traveled through those pathways. No single factor or combination accounted for more than 50% of the observed effect, leaving substantial residual benefit unexplained by conventional mediators.

The finding reframes semaglutide from a weight-loss adjunct to a direct cardiovascular therapeutic. Prior trials in type 2 diabetes (SUSTAIN-6, LEADER) showed similar event reductions, yet mediation was also incomplete; SELECT extends this pattern to a nondiabetic population. Proposed mechanisms include anti-inflammatory actions on vascular endothelium, direct myocardial effects, or natriuretic-peptide modulation, none of which were fully captured by the measured biomarkers.

Limitations include reliance on two-year risk-factor snapshots during the COVID-19 period, potential unmeasured confounding from frailty-related weight loss, and the absence of imaging or biomarker panels that could test alternative pathways. Next steps require dedicated mechanistic trials with serial coronary imaging, inflammatory proteomics, and longer follow-up to determine whether the unexplained benefit persists or attenuates after weight stabilization.